The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
Constellation Pharmaceuticals Inc. | COM | 210373106 | 75,647 | 2,626,631 | SH | SOLE | 0 | 2,626,631 | 0 | ||
Gritstone Oncology Inc | COM | 39868T105 | 3,426 | 869,493 | SH | SOLE | 0 | 869,493 | 0 | ||
Revolution Medicines Inc | COM | 76155X100 | 141,742 | 3,580,252 | SH | SOLE | 0 | 3,580,252 | 0 | ||
RAPT Therapeutics Inc | COM | 75382E109 | 76,742 | 3,885,679 | SH | SOLE | 0 | 3,885,679 | 0 | ||
ORIC Pharmaceuticals Inc. | COM | 68622P109 | 161,403 | 4,768,181 | SH | SOLE | 0 | 4,768,181 | 0 | ||
NGM Biopharmaceuticals Inc | COM | 62921N105 | 466,502 | 15,396,116 | SH | SOLE | 0 | 15,396,116 | 0 | ||
Nurix Therapeutics Inc | COM | 67080M103 | 177,004 | 5,383,333 | SH | SOLE | 0 | 5,383,333 | 0 |